Comparison of the serum fibrin‑fibrinogen degradation products with cytokeratin 19 fragment as biomarkers in patients with lung cancer

So,Hee  Jin; Hong,Seok‑Il; Lee,Jin  Kyung; Chang,Yoon  Hwan; Kang,Sun  Jung; Hong,Young  Jun

doi:10.3892/br.2014.315

Comparison of the serum fibrin‑fibrinogen degradation products with cytokeratin 19 fragment as biomarkers in patients with lung cancer

Authors:
- Hee Jin So
- Seok‑Il Hong
- Jin Kyung Lee
- Yoon Hwan Chang
- Sun Jung Kang
- Young Jun Hong
View Affiliations

Affiliations: Department of Laboratory Medicine, Korea Cancer Center Hospital, Seoul 139-709, Republic of Korea
Published online on: July 11, 2014 https://doi.org/10.3892/br.2014.315
Pages: 737-742

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is one of the main causes of cancer‑related mortality. The identification of early diagnostic biomarkers improved outcomes for lung cancer patients. Serum fibrin‑fibrinogen degradation products (FDP) levels are elevated in numerous malignancies due to hemostatic alterations. The serum FDP levels were compared to the levels of cytokeratin 19 fragment antigen (CYFRA 21‑1), another well‑established biomarker. The serum samples from 193 lung cancer patients, 84 healthy controls and 106 patients with benign respiratory diseases were obtained. The serum FDP level was measured using the DR‑70 immunoassay and the CYFRA 21‑1 level was measured by electrochemiluminescence using the Roche Analytics E170. Receiver operating characteristics curves were used to assess the predictive sensitivity and specificity. The mean serum FDP level in lung cancer patients (35.01±229.02 µg/ml) was significantly higher compared to the 190 non‑cancerous subjects (0.60±0.75 µg/ml; P=0.039). The mean serum CYFRA 21‑1 level in lung cancer patients (4.50±6.67 ng/ml) was also significantly higher compared to the non‑cancerous subjects (1.40±0.83 ng/ml; P<0.05). FDP exhibited clinical sensitivity and specificity of 86 and 75%, respectively, at an optimal cut‑off at 0.67 µg/ml. CYFRA 21‑1 exhibited clinical sensitivity and specificity of 77 and 74%, respectively, at a cut‑off of 1.65 ng/ml. The serum FDP area under the curve (0.87) was slightly higher compared to CYFRA 21‑1 (0.83). Therefore, it is apparent that serum FDP is comparable to CYFRA 21‑1 as a lung cancer biomarker and can be used for clinical practice.

View Figures

View References

1	Kim HR, Oh IJ, Shin MG, et al: Plasma proGRP concentration is sensitive and specific for discriminating small cell lung cancer from nonmalignant conditions or non-small cell lung cancer. J Korean Med Sci. 26:625–630. 2011. View Article : Google Scholar : PubMed/NCBI
2	Jung KW, Won YJ, Kong HJ, et al: Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010. Cancer Res Treat. 45:1–14. 2013. View Article : Google Scholar : PubMed/NCBI
3	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
4	van Zandwijk N: New methods for early diagnosis of lung cancer. Lung Cancer. 38:S9–S11. 2002.PubMed/NCBI
5	Altiay G, Ciftci A, Demir M, et al: High plasma D-dimer level is associated with decreased survival in patients with lung cancer. Clin Oncol (R Coll Radiol). 19:494–498. 2007. View Article : Google Scholar : PubMed/NCBI
6	Falanga A and Rickles FR: Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost. 25:173–182. 1999. View Article : Google Scholar : PubMed/NCBI
7	Kwaan HC and Keer HN: Fibrinolysis and cancer. Semin Thromb Hemost. 16:230–235. 1990. View Article : Google Scholar
8	Unsal E, Atalay F, Atikcan S and Yilmaz A: Prognostic significance of hemostatic parameters in patients with lung cancer. Respir Med. 98:93–98. 2004. View Article : Google Scholar : PubMed/NCBI
9	Wu D, Zhou X, Yang G, et al: Clinical performance of the AMDL DR-70 immunoassay kit for cancer detection. J Immunoassay. 19:63–72. 1998. View Article : Google Scholar : PubMed/NCBI
10	Oya M, Akiyama Y, Yanagida T, Akao S and Ishikawa H: Plasma D-dimer level in patients with colorectal cancer: its role as a tumor marker. Surg Today. 28:373–378. 1998. View Article : Google Scholar : PubMed/NCBI
11	Gerner C, Steinkellner W, Holzmann K, et al: Elevated plasma levels of crosslinked fibrinogen gamma-chain dimer indicate cancer-related fibrin deposition and fibrinolysis. Thromb Haemost. 85:494–501. 2001.
12	Lin SZ, Chen CC, Lee KC, et al: DR-70 immunoassay for the surveillance of hepatocellular carcinoma. J Gastroenterol Hepatol. 27:547–552. 2012. View Article : Google Scholar : PubMed/NCBI
13	Stieber P, Dienemann H, Hasholzner U, et al: Comparison of cytokeratin fragment 19 (CYFRA 21–1), tissue polypeptide antigen (TPA) and tissue polypeptide specific antigen (TPS) as tumour markers in lung cancer. Eur J Clin Chem Clin Biochem. 31:689–694. 1993.
14	Pujol JL, Grenier J, Daurès JP, Daver A, Pujol H and Michel FB: Serum fragment of cytokeratin subunit 19 measured by CYFRA 21–1 immunoradiometric assay as a marker of lung cancer. Cancer Res. 53:61–66. 1993.PubMed/NCBI
15	Takada M, Masuda N, Matsuura E, et al: Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay. Br J Cancer. 71:160–165. 1995. View Article : Google Scholar : PubMed/NCBI
16	Stieber P, Hasholzner U, Bodenmuller H, et al: CYFRA 21-1. A new marker in lung cancer. Cancer. 72:707–713. 1993. View Article : Google Scholar : PubMed/NCBI
17	Ma J, Gong Q, Lin M, et al: Combined five tumor markers in detecting primary hepatic carcinoma. Zhonghua Wai Ke Za Zhi. 38:14–16. 2000.(In Chinese).
18	Kerber A, Trojan J, Herrlinger K, Zgouras D, Caspary WF and Braden B: The new DR-70 immunoassay detects cancer of the gastrointestinal tract: a validation study. Aliment Pharmacol Ther. 20:983–987. 2004. View Article : Google Scholar : PubMed/NCBI
19	Li X, Qiao Z, Long X, Wei J and Cheng Y: Serum concentration of AMDL DR-70 for the diagnosis and prognosis of carcinoma of the tongue. Br J Oral Maxillofac Surg. 43:513–515. 2005. View Article : Google Scholar : PubMed/NCBI
20	Lee KH, Cho DH, Kim KM, Kim SM and Lee DJ: Meaning of the DR-70(TM) immunoassay for patients with the malignant tumor. Immune Netw. 6:43–51. 2006. View Article : Google Scholar
21	Shimwell NJ, Wei W, Wilson S, et al: Assessment of novel combinations of biomarkers for the detection of colorectal cancer. Cancer Biomark. 7:123–132. 2010.PubMed/NCBI
22	Ward DG, Wei W, Buckels J, et al: Detection of pancreatic adenocarcinoma using circulating fragments of fibrinogen. Eur J Gastroenterol Hepatol. 22:1358–1363. 2010. View Article : Google Scholar : PubMed/NCBI
23	Small-Howard AL and Harris H: Advantages of the AMDL-ELISA DR-70 (FDP) assay over carcinoembryonic antigen (CEA) for monitoring colorectal cancer patients. J Immunoassay Immunochem. 31:131–147. 2010. View Article : Google Scholar : PubMed/NCBI
24	Buccheri G, Torchio P and Ferrigno D: Plasma levels of D-dimer in lung carcinoma: clinical and prognostic significance. Cancer. 97:3044–3052. 2003. View Article : Google Scholar : PubMed/NCBI
25	Pavey SJ, Hawson GA and Marsh NA: Impact of the fibrinolytic enzyme system on prognosis and survival associated with non-small cell lung carcinoma. Blood Coagul Fibrinolysis. 12:51–58. 2001. View Article : Google Scholar : PubMed/NCBI
26	Brambilla E, Travis WD, Colby TV, et al: The new World Health Organization classification of lung tumours. Eur Respir J. 18:1059–1068. 2001. View Article : Google Scholar : PubMed/NCBI
27	Fields A, Poppema S and Jha Nl: Serum levels of circulating extracellular matrix complex (CEMC) in lung cancer patients: potential use as a tumor marker. In: 12th International Conference on Human Tumor Markers; New York, USA. June 11–14, 1995;
28	Wu D, Zhou X, Anderson G, et al: Sensitivity and specificity of DR-70 lung cancer immunology. Anal Lett. 32:1351–1362. 1999. View Article : Google Scholar
29	Ding L, Ping S and Jingmei Y: Application of tumor marker of DR-70 in the diagnosis of malignant tumors. Chongqing Med J. 28:1–3. 1999.
30	Kao CH, Hsieh JF, Ho YJ, Tsai SC and Lee JK: Cytokeratin fragment 19 (CYFRA 21-1) in healthy smokers. Anticancer Res. 19:4545–4546. 1999.PubMed/NCBI